Salarius Pharmaceuticals Inc
SLRX
Company Profile
Business description
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Contact
2450 Holcombe Boulevard
Suite X
HoustonTX77021
USAT: +1 713 913-5608
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,774.80 | 86.80 | 1.00% |
| CAC 40 | 7,537.57 | 52.09 | -0.69% |
| DAX 40 | 23,269.01 | 81.54 | -0.35% |
| Dow JONES (US) | 42,581.78 | 374.96 | 0.89% |
| FTSE 100 | 8,758.04 | 16.61 | -0.19% |
| HKSE | 24,189.48 | 500.35 | 2.11% |
| NASDAQ | 19,630.97 | 183.56 | 0.94% |
| Nikkei 225 | 38,790.56 | 436.47 | 1.14% |
| NZX 50 Index | 12,467.48 | 65.17 | -0.52% |
| S&P 500 | 6,025.17 | 57.33 | 0.96% |
| S&P/ASX 200 | 8,555.50 | 80.60 | 0.95% |
| SSE Composite Index | 3,418.11 | 36.53 | 1.08% |